6575-28-6

Basic information

• Product Name: Benzaldehyde, 2,6-dichloro-, oxime, (E)-
• CAS NO: 6575-28-6
• Molecular Formula: C7H5Cl2NO
• Molecular Weight: 190.029
• Mol File: 6575-28-6.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: Benzaldehyde, 2,6-dichloro-, oxime, (E)-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzaldehyde, 2,6-dichloro-, oxime, (E)-(6575-28-6)
• EPA Substance Registry System: Benzaldehyde, 2,6-dichloro-, oxime, (E)-(6575-28-6)

Safety Data

• Hazardous Substances Data: 6575-28-6(Hazardous Substances Data)

Upstream product

• 83-38-5 2,6-dichlorobenzaldehyde 

Downstream Products

• 121197-55-5 C₁₉H₁₄Cl₂NOP 
• 1194-65-6 2,6-dichloro-benzonitrile 
• 55151-92-3 3-(2,6-dichlorophenyl)-5-methyl-1,2,4-oxadiazole 
• 50-30-6 2,6-dichlorobenzoic acid 
• 946426-94-4 4-(bromomethyl)-5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazole 
• 946426-88-6 5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazole-4-carboxylic acid methyl ester 

Relevant articles and documents

Discovery of novel ketoxime ether derivatives with potent FXR agonistic activity, oral effectiveness and high liver/blood ratio

The farnesoid X receptor (FXR) is a promising therapeutic target for nonalcoholic steatohepatitis (NASH) and other bile acid related diseases because it plays a critical role in fibrosis, inflammation and bile acid homeostasis. Obeticholic acid (OCA), a FXR agonist which was synthesized from chenodeoxycholic acid, showed desirable curative effects in clinical trials. However, the pruritus which was the main side effect of OCA limited its further applications in NASH. Although pruritus was also observed in the clinical trials of non-steroidal FXR agonists, the proportion of patients with pruritus was much smaller than that of OCA. Thus, we decided to develop non-steroidal FXR agonists and discovered a series of novel FXR agonists which were synthesized from GW4064 by replacing the stilbene group with ketoxime ether. Encouragingly, in the following biological tests, our target compounds 13j and 13z not only showed potent FXR agonistic activities in vitro, but also effectively promoted the expression of target genes in vivo. More importantly, in the pharmacokinetic experiments, compounds 13j and 13z displayed high liver/blood ratio characteristics which were helpful to reduce the potential side effects which were caused by prolonged systemic activation of FXR. In summary, our compounds were good choices for the development of non-steroidal FXR agonists and were deserved further investigation.

Heterocyclic farnesoid X receptor modifier

The invention relates to a preparation method of a heterocyclic compound and a composition with components the same as those of the heterocyclic compound and application of the heterocyclic compound as a farnesoid X receptor active modifier. The modifier is the heterocyclic compound shown as the formula I or salt acceptable pharmaceutically or a predrug or a solvent compound or a polycrystal or an isomer or a stable isotope derivative. The compound can be used for treating or preventing related diseases mediated by FXR, and the related diseases are caused by saccharide or lipid or bile metabolic disturbance. The formula I is shown in the specification.

Novel FXR (NR1H4) binding and activity modulating compounds

The present invention relates to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of the NR1H4 receptor (FXR). The invention further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds, and to a process for the synthesis of said compounds.